{"product_id":"ewing-sarcoma-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape","title":"Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape","description":"\u003cp\u003eEwing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape\u003cbr\u003e\nSummary\u003c\/p\u003e\n\n\u003cp\u003eThis reports provides a data-driven overview of the current and future competitive landscape in Ewing Sarcoma therapeutics.There will be only 9,457 diagnosed prevalent cases of ES in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for ES.There are currently 11 marketed drugs for ES, the majority of which are DNA synthesis inhibitors.R\u0026amp;D activity in ES is very strong in mid-stage, with 32 drugs in Phase II of development.Clinical trial activity in ES was substantial during the past 10 years with 193 trials conducted overall.Partnerships were the most common deal type executed globally in the ES space.Scope\u003c\/p\u003e\n\n\u003cp\u003eGlobalData’s Ewing Sarcoma: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.\u003c\/p\u003e\n\n\u003cp\u003eComponents of the report include -Disease LandscapeDisease OverviewEpidemiology OverviewTreatment OverviewMarketed Products AssessmentBreakdown by Route of AdministrationProduct Profiles with Sales ForecastPricing and Reimbursement AssessmentAnnual Therapy CostTime to Pricing and Time to ReimbursementPipeline AssessmentBreakdown by Development Stage, Molecule Type, Route of AdministrationProduct Profiles with Sales ForecastLate-to-mid-stage Pipeline DrugsPhase Transition Success Rate and Likelihood of ApprovalClinical Trials AssessmentBreakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint StatusEnrolment Analytics, Site Analytics, Feasibility AnalysisDeals LandscapeMergers, Acquisitions, and Strategic Alliances by RegionOverview of Recent DealsCommercial AssessmentKey Market PlayersFuture Market CatalystsReasons to BuyDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.Develop business strategies by understanding the trends shaping and driving the Ewing Sarcoma market.Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ewing Sarcoma market in the future.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 74 Pages \/ MCW16230922","offer_id":47647231476018,"sku":null,"price":4194.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/ewing-sarcoma-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}